Condition

Dengue clinical trials and research

• 12Clinical trials
• 71NIH research projects
• 13Countries

Newest Dengue clinical trials

All recruiting trials (12)

• Dengue virus challenge in healthy adults to study immune responses

  Researchers will infect healthy adults with a weakened dengue virus to see how their bodies respond and how past exposure affects the reaction.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07706686

• Gut leakage in dengue: is the intestinal barrier affected during infection?

  Researchers are studying whether dengue infection disrupts the gut barrier and if that contributes to severe disease in adults with dengue who are in hospital.

  Recruiting University of Oxford · Chittagong, Chattogram Division · NCT07602920

• CP-COV03 versus placebo for adults with dengue or dengue-like illness

  This trial tests whether taking CP-COV03 for seven days helps adults with dengue (or dengue-like illnesses) recover faster and lower their viral levels compared with a placebo.

  Recruiting at 2 sites Phase 2/3 Hyundai Bioscience Co., Ltd. · Hanoi and 1 other locations · NCT07576868

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Immune responses in dengue and sepsis

  This project will collect blood from people hospitalized with dengue-like illness or sepsis and from healthy volunteers to see how their immune responses change over time.

  Recruiting at 4 sites Institut Pasteur du Cambodge · Kampong Speu and 3 other locations · NCT07040202

• Emetine for Dengue: seeing if a pill can help adults with dengue work better

  This study tests three groups—emetine 6 mg, emetine 12 mg, or a placebo—to see if a 7-day oral course can improve outcomes for adults with dengue.

  Recruiting Phase 2/3 Johns Hopkins University · Baltimore, Maryland and 1 other locations · NCT07016321

• Risk factors for hospitalization and transfusion criteria in dengue patients

  This project will try to find which clinical signs and lab results predict whether people aged 5 and up with confirmed dengue will need hospitalization or a blood transfusion.

  Recruiting Clinica Mexico · Piedras Negras, Coahuila · NCT07007585

• Using Wolbachia-infected mosquitoes to reduce dengue transmission

  This study is testing if releasing special mosquitoes that carry Wolbachia can help lower the number of dengue cases in certain neighborhoods in Singapore.

  Recruiting National Environment Agency, Singapore · Singapore · NCT06894901

• Using Montelukast to Prevent Liver Issues in Adult Dengue Patients

  This study is testing if the medication montelukast can help prevent liver problems in adults with dengue fever.

  Recruiting Phase 2/3 Phramongkutklao College of Medicine and Hospital · Bangkok · NCT06747130

• Adaptive platform testing antiviral medicines and a monoclonal antibody for early dengue

  This trial tests whether antiviral pills (molnupiravir or remdesivir) or a dengue monoclonal antibody can reduce the virus and help people with early dengue (within 48 hours of fever).

  Recruiting Phase 2 Oxford University Clinical Research Unit, Vietnam · Kuala Lumpur and 1 other locations · NCT06551844

• Assessing the effects of EYU688 on dengue fever

  This study is testing a new treatment called EYU688 to see if it can help people with dengue fever feel better and recover faster compared to a placebo.

  Recruiting at 26 sites Phase 2 Novartis · Manaus, Amazonas and 26 other locations · NCT06006559

• Dengue vaccination strategy for children in the French Caribbean

  This study is trying to see how many children in Martinique and Guadeloupe have been exposed to dengue and whether parents are open to giving them the Dengvaxia® vaccine.

  Recruiting University Hospital Center of Martinique · Fort-de-France · NCT04839757

NIH-funded research (newest 40 of 71)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Immune responses linked to severe dengue in children (primary infection)

  This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.

  NIH research Emory University · Atlanta, United States · NIH-11596504

• Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection

  A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.

  NIH research Emory University · Atlanta, United States · NIH-11590657

• Protective dengue vaccines that steer T and B cell responses

  A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.

  NIH research University of Illinois at Chicago · Chicago, UNITED STATES · NIH-11572336

• Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections

  A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.

  NIH research Stanford University · Stanford, United States · NIH-11563771

• Defining immune markers predicting protection against dengue in a long-term family study in Thailand

  This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.

  NIH research Upstate Medical University · Syracuse, United States · NIH-11563694

• Understanding dengue protection in children from a long-term Thai family cohort

  A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.

  NIH research Upstate Medical University · Syracuse, United States · NIH-11563693

• A T cell vaccine approach to prevent Dengue and Zika infections

  A new vaccine approach aims to teach the immune system’s T cells to recognize and fight Dengue and Zika viruses without triggering harmful antibody responses.

  NIH research Georgia State University · Atlanta, United States · NIH-11520651

• How the immune system responds to dengue vaccines and infection

  This project compares immune reactions in people given different dengue vaccine formulations to find why one vaccine fully prevented DENV-2 infection while another did not.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11481645

• Proyecto Tariki: Community-driven dengue prevention and response

  This project helps communities in Peru use neighborhood-led actions and a mobile platform to reduce mosquito breeding and dengue illness.

  NIH research Tulane University of Louisiana · New Orleans, United States · NIH-11462453

• Dengue virus from the woods: how sylvatic strains could affect people

  Researchers are studying whether sylvatic dengue viruses, which live in forests, can infect human cells and potentially spill over to people.

  NIH research University of Colorado · Boulder, UNITED STATES · NIH-11455116

• Dengue virus NS4A protein dynamics shape how the virus hijacks cells

  This grant studies how a dengue virus protein (NS4A) helps the virus bend cell membranes, aiming to reveal new ways to stop infection.

  NIH research University of California at Davis · Davis, United States · NIH-11453454

• Dengue vaccine study using two vaccines together to strengthen and broaden immunity

  A Phase 2b trial tests whether giving TAK-003 followed by Butantan-DV boosts broad, durable antibodies against dengue in adults who have been vaccinated before.

  NIH research Emory University · Atlanta, United States · NIH-11418927

• Understanding dengue in Bamako: how common severe dengue is and what raises risk

  This project study aims to understand how dengue fever spreads and what factors make severe illness more likely among people in urban Bamako, Mali.

  NIH research Univ of Sciences, Tech & Tech of Bamako · Bamako, Mali · NIH-11417996

• How prior dengue infections shape T cell responses after a new infection or vaccine

  This project looks at how a person’s existing dengue immunity affects their body's T cell response when exposed to a different dengue serotype or a live dengue vaccine, with a focus on kids and how this influences protection and safety.

  NIH research University of California Berkeley · Berkeley, United States · NIH-11415564

• Tetravalent dengue vaccines: how your B cells and antibodies respond to protect you from dengue or possibly worsen it

  This project looks at how vaccine-made antibodies and B cells respond to dengue and what determines protection versus disease enhancement in children who received a tetravalent live attenuated dengue vaccine.

  NIH research University of California Berkeley · Berkeley, United States · NIH-11415558

• Dengue immunity in kids: how antibodies and B cells respond to one or more dengue types

  A funded project in Nicaragua and at UC Berkeley explores how children’s antibody and B cell responses to dengue differ across the four virus types and over time.

  NIH research University of California Berkeley · Berkeley, United States · NIH-11415550

• Protective immunity after dengue infections and vaccination

  Researchers are studying how our immune system remembers dengue and how vaccines influence that protection, aiming to spot clues that predict who remains protected or at risk after infection or vaccination.

  NIH research University of California Berkeley · Berkeley, United States · NIH-11415532

• Improving dengue virus genome tracking and variant detection

  Creating easier and faster ways to read dengue virus genes to help health teams and people in dengue-prone areas.

  NIH research Yale University · New Haven, United States · NIH-11407931

• Immune responses linked to severe primary dengue in children

  This project studies why some children with their first dengue infection get very sick by looking closely at their immune system.

  NIH research Emory University · Atlanta, United States · NIH-11406918

• Dengue immunity markers to predict protection or risk

  We’re studying how the body’s antibodies and immune cells relate to protection against dengue and to illness after infection or vaccination.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11401808

• Antibody-Driven Dengue Severity: How IgG Shapes Dengue Risk

  This grant explores how certain dengue antibodies may make illness worse and what that means for vaccines and therapies.

  NIH research Rockefeller University · New York, United States · NIH-11397299

• Correlates of protection from dengue in a long-term family cohort in Thailand

  This project looks at how children’s early exposure to flaviviruses shapes protection against dengue for future infections in a long-running family cohort in Thailand.

  NIH research Upstate Medical University · Syracuse, United States · NIH-11394407

• New antiviral agents to fight Zika and dengue viruses

  A tiny grant to test new antiviral drugs that could help people, especially children and families in affected regions, fight Zika and dengue viruses.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11378557

• B cell receptors may drive dengue infection and severity

  A study from Upstate Medical University explores how B cells and their receptors might influence dengue virus infection and the body’s response in people who get dengue.

  NIH research Upstate Medical University · Syracuse, United States · NIH-11369986

• Dengue vaccine-B cell and T cell responses linked to protection after controlled dengue infection

  A Johns Hopkins-led study will look at how the body’s B and T cells respond to dengue vaccines and how these responses relate to protection against dengue infection in people who participate in a controlled infection model.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11365993

• Understanding how dengue virus makes its RNA to help create antivirals and vaccines

  Researchers study how the dengue virus copies its RNA inside cells to find targets for new antiviral medicines and vaccines.

  NIH research Trustees of Indiana University · Bloomington, United States · NIH-11362342

• Designing dengue protein vaccines that protect without making disease worse

  Researchers are making new dengue protein vaccines to help children and others produce protective antibodies while avoiding antibody responses that can make dengue more severe.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11326175

• How long dengue vaccine protection lasts in areas where dengue is common

  This project looks at immune responses after dengue vaccination to find which people keep protection longest in places where dengue is common.

  NIH research University of Rhode Island · Kingston, United States · NIH-11309098

• A weakened live vaccine meant to protect against all four dengue virus types

  This project is developing a weakened live vaccine to provide long-lasting protection against all four dengue viruses for children and adults, including people who have never had dengue.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11285314

• Tariki: Community-led dengue prevention at home

  This program helps neighborhood residents use simple household actions and a phone-based tool to reduce mosquitoes and lower dengue risk in their communities.

  NIH research Tulane University of Louisiana · New Orleans, United States · NIH-11224050

• Why some people get severe dengue during their first infection

  This project looks at how the immune system responds in people who develop severe dengue the first time they are infected.

  NIH research Emory University · Atlanta, United States · NIH-11190950

• A new treatment for dengue using combined antibodies

  This study is working on a new treatment for dengue fever that combines two powerful antibodies into one, making it stronger and easier to produce, so it can help kids and others affected by the disease feel better with a smaller dose.

  NIH research Mapp Biopharmaceutical, INC. · San Diego, United States · NIH-11185642

• Blood markers of protection and risk after dengue vaccination or infection

  This work looks for blood antibodies and immune signals that show whether people are protected from dengue or at higher risk after vaccination or past infection.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11176226

• A new vaccine to prevent Dengue and Zika virus infections

  This study is testing a new vaccine designed to help protect kids and others from getting sick with Dengue and Zika viruses, which are spread by mosquito bites, by safely boosting the immune system to fight off these viruses.

  NIH research Loyola University Chicago · Maywood, United States · NIH-11167318

• Finding markers that indicate protection or risk from dengue vaccines and infections

  This study is looking at how our immune system reacts to dengue, whether from getting the virus or from vaccines, to find out what signs can show if someone might get severe dengue or be safe from it, and it involves checking blood samples from people over several years to see how these immune responses change.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11159254

• Why some dengue antibodies make illness worse

  This work checks whether certain antibodies in people who had dengue before can make later dengue infections more severe.

  NIH research Rockefeller University · New York, United States · NIH-11158664

• Understanding How Dengue Virus Copies Itself

  This project aims to understand how viruses like dengue, West Nile, and Zika make copies of their genetic material, which could help create new treatments and vaccines for people affected by these diseases.

  NIH research Trustees of Indiana University · Bloomington, United States · NIH-11144982

• Antivirals that activate inside the body against Zika and dengue

  Developing antiviral medicines that activate inside human cells to stop Zika and dengue infections.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11133060

• How early dengue exposures shape immunity in Thai families

  Researchers are following multigenerational households in Thailand to learn how children’s earliest exposures to dengue and related viruses change their chances of getting sick later.

  NIH research Upstate Medical University · Syracuse, United States · NIH-11120938

• How past dengue infection or vaccination shapes T cell immunity

  This project looks at how previous dengue infections or a weakened dengue vaccine change T cells in children and others exposed to dengue.

  NIH research University of California Berkeley · Berkeley, United States · NIH-11111758

Related topics

Quick answers

How many Dengue clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in Vietnam (3 trials), Singapore (2 trials), Malaysia (2 trials), Mexico (2 trials), United States (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2/3: 3, Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →